Rare(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
Appearance of blisters on the skin, mouth, eyes, or genitals – may be signs of "toxic epidermal necrolysis" or "Stevens-Johnson syndrome" ordrug reaction with eosinophilia and systemic symptoms (DRESS).DRESS initially appears as flu-like symptoms and a rash on the face, followed by a prolonged rash with high temperature, elevated liver enzymes observed in blood tests, and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes.
Inform your doctor or nurse immediately if you experience any of the side effects mentioned above.
Inform your doctor or nurse immediately if you experience any of the following severe side effects – you may need urgent medical treatment:
Rare(may affect up to 1 in 100 people)
Unknown frequency(cannot be estimated from available data)
Inform your doctor or nurse immediately if you experience any of the side effects mentioned above.
Other side effects
Talk to your doctor, pharmacist, or nurse if you experience any of the following side effects:
Common(may affect up to 1 in 10 people)
Rare(may affect up to 1 in 100 people)
Rare(may affect up to 1 in 1,000 people)
Unknown frequency(cannot be estimated from available data)
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly throughthe Spanish System for Pharmacovigilance of Medicines for human use:www.notificaRAM.es.By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and vial label after CAD. The expiration date is the last day of the month indicated.
For powder and solvent:
Store below 25°C. Store the container in the outer packaging to protect it from light.
For single use only.
Discard any unused solution.
The information about conservation and the time to use Teicoplanin Noridem once it is reconstituted and ready for use is detailed in “Practical information for healthcare professionals on the preparation and handling of Teicoplanin Noridem”.
Composition of Teicoplanin Noridem
Each mL of reconstituted solution contains 133.4 mg of teicoplanin.
Appearance of the product and contents of the package
Teicoplanin Noridem is a powder and solvent for injectable and infusible solution or oral solution.
The powder is a white to off-white powder. The solvent is a transparent and colorless solution.
The powder is packaged:
Presentations:
1 vial of 400 mg + 1 ampoule of 3 mL of solvent
10 vials of 400 mg + 10 ampoules of 3 mL of solvent
Only some package sizes may be commercially available.
Marketing authorization holder and responsible manufacturer
Marketing authorization holder:Noridem Enterprises Ltd., Evagorou & Makariou, Mitsi Building 3, Office 115, 1065 Nicosia, Cyprus.
Responsible manufacturer:DEMO S.A., 21st km National Road Athens-Lamia, 14568 Krioneri, Attica, Greece.
This medicinal product is authorized in the member states of the European Economic Area with the following names::
United Kingdom | Teicoplanin 400 mg Powder and Solvent for Solution for injection/infusion or oral solution |
Austria | Teicoplanin Noridem 400 mg Pulver und Lösungsmittel zur Herstellung einer Injektion-/Infusionslösung oder einer Lösung zum Einnehmen |
Germany | Teicoplanin Noridem 400 mg Pulver und Lösungsmittel zur Herstellung einer Injektions-/Infusionslösung oder einer Lösung zum Einnehmen |
Greece | Teicoplanin Noridem 400 mg Κ?νις και διαλ?της για παρασκευ? ενεσ?μου διαλ?ματος ? διαλ?ματος προς ?γχυση |
Spain | Teicoplanina Noridem 400 mg Polvo y disolvente para solución inyectable y para perfusión EFG |
Ireland | Teicoplanin 400 mg Powder and Solvent for Solution for injection/infusion or oral solution |
Last review date of this leaflet: 10/2022.
This information is intended solely for healthcare professionals:
Practical information for healthcare professionals on the preparation and handling of Teicoplanin Noridem. This medicinal product is for single use only.Dispose of any unused solution. The reconstitution/dilution must be performed in aseptic conditions. Before administration, the solution must be visually inspected for particles and color change. Only the solution should be used if it is transparent and free of particles. Administration form Teicoplanin must be administered intravenously or intramuscularly.The intravenous injection can be administeredas a bolus over 3-5 minutes or by infusion over 30 minutes. In newborn babies, only administration by infusion will be used. For diarrhea and colitis associated with Clostridioides difficile infection, oral administration should be used. Preparation of the reconstituted solution: The solution is reconstituted by adding all the contents of the solvent supplied to the 200 mg and 400 mg powder vial. Water is added slowly to the vial, which must be rotated until all the powder is dissolved to prevent foam formation. If foam develops, allow the solution to stand for approximately 15 minutes for the foam to dissipate. Only transparent and yellowish solutions should be used. The reconstituted solutions will contain400 mg of teicoplanin in 3.0 mL The final solution is isotonic with plasma and has a pH of 7.2-7.8.
The reconstituted solution can be injected directly or alternatively diluted, or administered orally. Preparation of the diluted solution before infusion Teicoplanin Noridem can be administered in the following infusion solutions:
Validity period of the reconstituted solution: Chemical and physical stability has been demonstrated in use for 24 hours between 2°C and 8°C. From a microbiological point of view, the product should be used immediately. If not used immediately, the storage times and conditions in use are the responsibility of the user and should not normally exceed 24 hours between 2°C and 8°C, unless reconstitution has been performed in controlled and validated aseptic conditions. Validity period of the diluted medicinal product: Chemical and physical stability in use of the reconstituted solution prepared as recommended has been demonstrated for 24 hours between 2 and 8°C. From a microbiological point of view, the medicinal product should be used immediately. If not used immediately, the storage times and conditions in use are the responsibility of the user and should not normally exceed 24 hours between 2 and 8°C, unless reconstitution/dilution has been performed in controlled and validated aseptic conditions. Elimination The disposal of unused medicinal product and all materials that have been in contact with it will be carried out in accordance with local regulations. |
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.